Cepheid’s CPHD rapid influenza and RSV assay – the Xpert Flu+RSV Xpress test – recently won the U.S. FDA 510(k) marketing approval and the Clinical Laboratory Improvement Achievements (CLIA) waiver.
SUNNYVALE, Calif., June 9, 2020 /PRNewswire/ -- Cepheid today announced the development of a next-generation test to assist global efforts in the fight against the spread of COVID-19 during the ...
Cepheid receives expanded US FDA clearance with CLIA waiver for Xpert Xpress multiplex vaginal panel
Cepheid announced that it has received US FDA clearance with Clinical Laboratory Improvement Amendments (CLIA) waiver for Xpert Xpress MVP. This multiplex vaginal panel can now be performed in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results